HC Wainwright Issues Pessimistic Estimate for NRIX Earnings

Key Points

• HC Wainwright has revised its FY2025 earnings per share estimate for Nurix Therapeutics down to ($3.18), compared to a previous estimate of ($2.76), while maintaining a "Buy" rating and a price target of $33.00.
• Nurix Therapeutics reported Q3 earnings of ($1.03) per share, falling short of analysts' expectations of ($0.84), with revenue of $7.89 million against anticipated $16.06 million.
• Insiders at Nurix Therapeutics have sold a total of 14,014 shares in the last quarter, indicating a 5.87% decrease in one insider's ownership following a sale.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Nurix Therapeutics in a report released on Tuesday, October 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($3.18) for the year, down from their previous estimate of ($2.76). HC Wainwright has a "Buy" rating and a $33.00 price target on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.99) EPS, Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($4.05) EPS.

A number of other research analysts have also weighed in on NRIX. Stephens reaffirmed an "overweight" rating and set a $30.00 target price on shares of Nurix Therapeutics in a report on Thursday, July 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nurix Therapeutics in a report on Wednesday, October 8th. UBS Group cut their price objective on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, July 10th. Wells Fargo & Company set a $22.00 price objective on Nurix Therapeutics in a report on Monday. Finally, Baird R W raised Nurix Therapeutics to a "strong-buy" rating in a report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $27.79.

Nurix Therapeutics Stock Up 12.7%

NRIX stock opened at $10.35 on Thursday. The firm has a market capitalization of $795.71 million, a PE ratio of -3.48 and a beta of 2.33. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56. The stock has a 50-day simple moving average of $9.46 and a two-hundred day simple moving average of $10.53.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.19). The company had revenue of $7.89 million for the quarter, compared to analysts' expectations of $16.06 million. Nurix Therapeutics had a negative net margin of 292.50% and a negative return on equity of 53.57%.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,308 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares in the company, valued at approximately $828,966.23. The trade was a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 5,402 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the sale, the chief financial officer owned 35,512 shares of the company's stock, valued at $391,697.36. The trade was a 13.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,014 shares of company stock valued at $163,014 in the last quarter. Corporate insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds have recently made changes to their positions in NRIX. Tower Research Capital LLC TRC increased its stake in shares of Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company's stock valued at $73,000 after buying an additional 3,475 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Nurix Therapeutics by 38.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after buying an additional 2,562 shares during the period. Velan Capital Investment Management LP purchased a new position in shares of Nurix Therapeutics during the second quarter valued at approximately $114,000. E Fund Management Co. Ltd. purchased a new position in shares of Nurix Therapeutics during the first quarter valued at approximately $122,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Nurix Therapeutics during the second quarter valued at approximately $141,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.